Skip to Main Content

Paper Details

Phase II study of peginterferon alpha-2b for patients with unresectable or recurrent craniopharyngiomas: a Pediatric Brain Tumor Consortium report.
Neuro Oncol
14
2020
CNS tumors, Craniopharyngiomas, PBTC, Pediatric Brain Tumor, Pegylated interferon alpha-, children, craniopharyngioma, craniopharyngiomas, patients, peginterferon alpha-2b, pegylated interferon alpha-2b
Author NameAffiliation
Stewart GoldmanAnn & Robert H. Lurie Children's Hospital of Chicago
Ian F PollackChildren's Hospital of Pittsburgh, University of Pittsburgh
Ian F PollackChildren's Hospital of Pittsburgh, University of Pittsburgh
Tina Young PoussaintBoston Children's Hospital
Tina Young PoussaintHarvard Medical School
Donald W ParsonsTexas Medical Center
Donald W ParsonsTexas Medical Center
Alberto BroniscerChildren's Hospital of Pittsburgh, University of Pittsburgh Medical Center
Giles W RobinsonSt Jude's Children's Research Hospital
Giles W RobinsonSt Jude's Children's Research Hospital
Sonia PartapStanford University School of Medicine
Sonia PartapStanford University School of Medicine
Lindsay KilburnChildren's National Medical Center
Lindsay KilburnChildren's National Medical Center
Maryam FouladiCincinnati Children's Hospital
  • 1 - 15

Datasets

Release 1.2